{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:28:13Z","timestamp":1793125693782,"version":"4.5.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.mayocp.2019.03.029","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T07:00:26Z","timestamp":1568876426000},"page":"2072-2086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Medication-Assisted Treatment for Opioid-Use Disorder"],"prefix":"10.1016","volume":"94","author":[{"given":"Tyler S.","family":"Oesterle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria J.","family":"Thusius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-4766","authenticated-orcid":false,"given":"Teresa A.","family":"Rummans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib1","first-page":"50","article-title":"The chemical history of morphine: an 8000-year journey, from resin to de-novo synthesis","volume":"3","author":"Brook","year":"2017","journal-title":"J\u00a0Anesth Hist"},{"issue":"7","key":"10.1016\/j.mayocp.2019.03.029_bib2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2174\/1381612043452974","article-title":"Pain treatment: a historical overview","volume":"10","author":"Sabatowski","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.mayocp.2017.12.020","article-title":"How good intentions contributed to bad outcomes: the opioid crisis","volume":"93","author":"Rummans","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.mayocp.2019.03.029_bib4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/jama.2017.0935","article-title":"History of the Joint Commission's pain standards: lessons for today's prescription opioid epidemic","volume":"317","author":"Baker","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.mayocp.2019.03.029_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.7326\/0003-4819-113-11-885","article-title":"Improving outcomes of analgesic treatment: is education enough?","volume":"113","author":"Max","year":"1990","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.029_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1524-9042(03)00033-X","article-title":"Accuracy of emergency nurses in assessment of patients' pain","volume":"4","author":"Puntillo","year":"2003","journal-title":"Pain Manag Nurs"},{"key":"10.1016\/j.mayocp.2019.03.029_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","article-title":"The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction","volume":"36","author":"Kolodny","year":"2015","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.mayocp.2019.03.029_bib8","series-title":"Pain and Disability: Clinical, Behavioral, and Public Policy Perspectives","year":"1987"},{"issue":"43","key":"10.1016\/j.mayocp.2019.03.029_bib9","first-page":"1487","article-title":"Vital signs: overdoses of prescription opioid pain relievers\u2013United States, 1999\u20132008","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.mayocp.2018.01.018","article-title":"Beyond supply: how we must tackle the opioid epidemic","volume":"93","author":"Srivastava","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.mayocp.2019.03.029_bib11","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/ajt.14905","article-title":"Overdose deaths involving opioids, cocaine, and psychostimulants\u2013United States, 2015\u20132016","volume":"18","author":"Seth","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.mayocp.2019.03.029_bib12","series-title":"World Drug Report 2018","year":"2018"},{"key":"10.1016\/j.mayocp.2019.03.029_bib13","series-title":"Annual Surveillance Report of Drug-Related Risks and Outcomes\u2013United States, 2017","year":"2017"},{"issue":"6","key":"10.1016\/j.mayocp.2019.03.029_bib14","article-title":"Medical and nonmedical use of prescription opioids: epidemiology and prevalence","volume":"36","author":"Morgan","year":"2006","journal-title":"Psychiatr Ann"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.029_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis","volume":"156","author":"Vowles","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.mayocp.2019.03.029_bib16","series-title":"CBHSQ Data Review","first-page":"1","author":"Muhuri","year":"2013"},{"key":"10.1016\/j.mayocp.2019.03.029_bib17","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"issue":"1-2","key":"10.1016\/j.mayocp.2019.03.029_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2013.01.007","article-title":"Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers\u2013United States, 2002-2004 and 2008-2010","volume":"132","author":"Jones","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.mayocp.2019.03.029_bib19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","article-title":"Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool","volume":"6","author":"Webster","year":"2005","journal-title":"Pain Med"},{"issue":"9","key":"10.1016\/j.mayocp.2019.03.029_bib20","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/AJP.0b013e3181f195ba","article-title":"Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy","volume":"26","author":"Butler","year":"2010","journal-title":"Clin J Pain"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1300\/J465v28n03_03","article-title":"Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse","volume":"28","author":"Babor","year":"2007","journal-title":"Subst Abuse"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2019.03.029_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/add.13675","article-title":"Screening, Brief Intervention and Referral to Treatment: implications of SAMHSA's SBIRT initiative for substance abuse policy and practice","volume":"112","author":"Babor","year":"2017","journal-title":"Addiction"},{"issue":"22","key":"10.1016\/j.mayocp.2019.03.029_bib23","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies: tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2019.03.029_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.029_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0193-953X(18)30190-4","article-title":"Opiate addiction and the locus coeruleus: the clinical utility of clonidine, naltrexone, methadone, and buprenorphine","volume":"16","author":"Gold","year":"1993","journal-title":"Psychiatr Clin North Am"},{"issue":"0","key":"10.1016\/j.mayocp.2019.03.029_bib26","first-page":"33","article-title":"Naloxone, naltrexone, and related noroxymorphones","volume":"8","author":"Blumberg","year":"1973","journal-title":"Adv Biochem Psychopharmacol"},{"key":"10.1016\/j.mayocp.2019.03.029_bib27","first-page":"147","article-title":"The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics and sustained-release preparations","author":"Willette","year":"1976","journal-title":"Natl Inst Drug Abuse Res"},{"issue":"9 pt 2","key":"10.1016\/j.mayocp.2019.03.029_bib28","first-page":"4","article-title":"The role of the National Institute on Drug Abuse in the development of naltrexone","volume":"45","author":"Ginzburg","year":"1984","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.mayocp.2019.03.029_bib29","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archpsyc.1997.01830240090013","article-title":"The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. The Naltrexone Usage Study Group","volume":"54","author":"Croop","year":"1997","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/med.2610020302","article-title":"Naltrexone, opiate addiction, and endorphins","volume":"2","author":"Gold","year":"1982","journal-title":"Med Res Rev"},{"key":"10.1016\/j.mayocp.2019.03.029_bib31","first-page":"Cd001333","article-title":"Oral naltrexone maintenance treatment for opioid dependence","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mayocp.2019.03.029_bib32","first-page":"147","article-title":"The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics","volume":"28","author":"Verebey","year":"1981","journal-title":"NIDA Res Monogr"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.029_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2013.05.030","article-title":"Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?","volume":"133","author":"Sullivan","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"10.1016\/j.mayocp.2019.03.029_bib34","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1176\/appi.ajp.2018.17101112","article-title":"Medications for alcohol and opioid use disorders and risk of suicidal behavior, accidental overdoses, and crime","volume":"175","author":"Molero","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.029_bib35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1360-0443.2006.01369.x","article-title":"Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review","volume":"101","author":"Johansson","year":"2006","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1300\/J251v03n03_03","article-title":"The sequential use of clonidine and naltrexone in the treatment of opiate addicts","volume":"3","author":"Gold","year":"1984","journal-title":"Adv Alcohol Subst Abuse"},{"key":"10.1016\/j.mayocp.2019.03.029_bib37","first-page":"185","article-title":"Naltrexone in addicted physicians and business executives","volume":"55","author":"Washton","year":"1984","journal-title":"NIDA Res Monogr"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1300\/J251v04n02_08","article-title":"Successful use of naltrexone in addicted physicians and business executives","volume":"4","author":"Washton","year":"1984","journal-title":"Adv Alcohol Subst Abuse"},{"issue":"9 pt 2","key":"10.1016\/j.mayocp.2019.03.029_bib39","first-page":"46","article-title":"Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience","volume":"45","author":"Ling","year":"1984","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"9 pt 2","key":"10.1016\/j.mayocp.2019.03.029_bib40","first-page":"49","article-title":"Naltrexone treatment in a jail work-release program","volume":"45","author":"Brahen","year":"1984","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0376-8716(94)90161-9","article-title":"Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts","volume":"34","author":"Navaratnam","year":"1994","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.029_bib42","first-page":"21","article-title":"High-dose naltrexone and liver function safety","volume":"6","author":"Marrazzi","year":"1997","journal-title":"Am J Addict"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.alcohol.2006.05.003","article-title":"Study of hepatotoxicity of naltrexone in the treatment of alcoholism","volume":"38","author":"Yen","year":"2006","journal-title":"Alcohol"},{"issue":"17","key":"10.1016\/j.mayocp.2019.03.029_bib44","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1080\/14656566.2016.1244529","article-title":"Update on pharmacotherapy for treatment of opioid use disorder","volume":"17","author":"Ayanga","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.mayocp.2019.03.029_bib45","doi-asserted-by":"crossref","DOI":"10.3310\/hta11060","article-title":"Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation","volume":"11","author":"Adi","year":"2007","journal-title":"Health Technol Assess"},{"issue":"5","key":"10.1016\/j.mayocp.2019.03.029_bib46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.euroneuro.2005.11.001","article-title":"A\u00a0systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence","volume":"16","author":"Roozen","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2-3","key":"10.1016\/j.mayocp.2019.03.029_bib47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.drugalcdep.2007.06.013","article-title":"Management of relapse in naltrexone maintenance for heroin dependence","volume":"91","author":"Sullivan","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.mayocp.2019.03.029_bib48","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1365-2362.2003.01218.x","article-title":"Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study","volume":"33","author":"Ahmadi","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.mayocp.2019.03.029_bib49","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0740-5472(02)00301-X","article-title":"Behavioral naltrexone therapy: an integrated treatment for opiate dependence","volume":"23","author":"Rothenberg","year":"2002","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.mayocp.2019.03.029_bib50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0740-5472(85)90036-4","article-title":"Naltrexone","volume":"2","author":"Kleber","year":"1985","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"9776","key":"10.1016\/j.mayocp.2019.03.029_bib51","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.029_bib52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s002130100909","article-title":"Depot naltrexone: long-lasting antagonism of the effects of heroin in humans","volume":"159","author":"Comer","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1176\/appi.ajp.2018.17070732","article-title":"A\u00a0randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder","volume":"176","author":"Sullivan","year":"2019","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.029_bib54","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/add.14448","article-title":"Long-acting naltrexone has long-acting benefits and 100% induction rates are not difficult to achieve","volume":"114","author":"Brewer","year":"2019","journal-title":"Addiction"},{"issue":"13","key":"10.1016\/j.mayocp.2019.03.029_bib55","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"issue":"10118","key":"10.1016\/j.mayocp.2019.03.029_bib56","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.mayocp.2019.03.029_bib57","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.mayocp.2019.03.029_bib58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.drugalcdep.2014.02.002","article-title":"Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial","volume":"138","author":"Mannelli","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mayocp.2019.03.029_bib59","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"suppl 8","key":"10.1016\/j.mayocp.2019.03.029_bib60","first-page":"S235","article-title":"Cost and utilization outcomes of opioid-dependence treatments","volume":"17","author":"Baser","year":"2011","journal-title":"Am J Manag Care"},{"issue":"5","key":"10.1016\/j.mayocp.2019.03.029_bib61","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5055\/jom.2005.0054","article-title":"A\u00a0comparison of oral and implant naltrexone outcomes at 12 months","volume":"1","author":"Colquhoun","year":"2005","journal-title":"J\u00a0Opioid Manag"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/dar.12095","article-title":"A\u00a0systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence","volume":"33","author":"Larney","year":"2014","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib63","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/1355621031000117446","article-title":"Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels","volume":"8","author":"Foster","year":"2003","journal-title":"Addict Biol"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2019.03.029_bib64","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"3-4","key":"10.1016\/j.mayocp.2019.03.029_bib65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0376-8716(85)90067-5","article-title":"Buprenorphine","volume":"14","author":"Lewis","year":"1985","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mayocp.2019.03.029_bib66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1749-6632.2011.06352.x","article-title":"The history of the development of buprenorphine as an addiction therapeutic","volume":"1248","author":"Campbell","year":"2012","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.mayocp.2019.03.029_bib67","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.drugalcdep.2018.05.010","article-title":"Tapering off and returning to buprenorphine maintenance in a primary care office based addiction treatment (OBAT) program","volume":"189","author":"Weinstein","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002130100920","article-title":"Blockade of hydromorphone effects by buprenorphine\/naloxone and buprenorphine","volume":"159","author":"Strain","year":"2002","journal-title":"Psychopharmacology"},{"issue":"15","key":"10.1016\/j.mayocp.2019.03.029_bib69","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1517\/14656566.2014.955469","article-title":"Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies","volume":"15","author":"Li","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.mayocp.2019.03.029_bib70","first-page":"358","article-title":"American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.mayocp.2019.03.029_bib71","first-page":"Cd011117","article-title":"Opioid agonist treatment for pharmaceutical opioid dependent people","author":"Nielsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib72","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/10826084.2017.1400064","article-title":"A\u00a0systematic, intensive statistical investigation of data from the Comprehensive Analysis of Reported Drugs (CARD) for compliance and illicit opioid abstinence in substance addiction treatment with buprenorphine\/naloxone","volume":"53","author":"Blum","year":"2018","journal-title":"Subst Use Misuse"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib73","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11606-008-0866-8","article-title":"Home buprenorphine\/naloxone induction in primary care","volume":"24","author":"Lee","year":"2009","journal-title":"J\u00a0Gen Intern Med"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.029_bib74","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jsat.2010.12.002","article-title":"A\u00a0comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions","volume":"40","author":"Cunningham","year":"2011","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"12","key":"10.1016\/j.mayocp.2019.03.029_bib75","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.029_bib76","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: an international review","volume":"4","author":"Yokell","year":"2011","journal-title":"Curr Drug Abuse Rev"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib77","first-page":"175","article-title":"Illicit use of buprenorphine\/naloxone among injecting and noninjecting opioid users","volume":"5","author":"Bazazi","year":"2011","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.mayocp.2019.03.029_bib78","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2018.09.007","article-title":"Understanding the use of diverted buprenorphine","volume":"193","author":"Cicero","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.mayocp.2019.03.029_bib79","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/10826080701434857","article-title":"Buprenorphine misuse in Finland","volume":"42","author":"Aalto","year":"2007","journal-title":"Subst Use Misuse"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib80","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.drugalcdep.2013.04.006","article-title":"Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes","volume":"132","author":"Schuman-Olivier","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib81","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1176\/ajp.155.3.447-b","article-title":"Six deaths linked to misuse of buprenorphine-benzodiazepine combinations","volume":"155","author":"Reynaud","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.mayocp.2019.03.029_bib82","series-title":"Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction","year":"2004"},{"key":"10.1016\/j.mayocp.2019.03.029_bib83","series-title":"Tip 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP) Series 40","author":"McNicholas","year":"2004"},{"key":"10.1016\/j.mayocp.2019.03.029_bib84","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2147\/DDDT.S72543","article-title":"Advances in the delivery of buprenorphine for opioid dependence","volume":"11","author":"Rosenthal","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.mayocp.2019.03.029_bib85","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2105\/AJPH.57.11.2005","article-title":"Selected bibliography on narcotic addiction treatment, 1960-1966: reports of treatment programs","volume":"57","author":"Dole","year":"1967","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.mayocp.2019.03.029_bib86","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","article-title":"A\u00a0medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride","volume":"193","author":"Dole","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.mayocp.2019.03.029_bib87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1360-0443.1968.tb05251.x","article-title":"The use of methadone for narcotic blockade","volume":"63","author":"Dole","year":"1968","journal-title":"Br J Addict Alcohol Other Drugs"},{"key":"10.1016\/j.mayocp.2019.03.029_bib88","series-title":"The National Research Council Involvement in the Opiate Problem, 1928-1971","author":"Eddy","year":"1973"},{"issue":"11","key":"10.1016\/j.mayocp.2019.03.029_bib89","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1517\/14656560903037168","article-title":"Opioid dependence treatment: options in pharmacotherapy","volume":"10","author":"Stotts","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"6960","key":"10.1016\/j.mayocp.2019.03.029_bib90","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/bmj.309.6960.997","article-title":"Methadone maintenance treatment in opiate dependence: a review","volume":"309","author":"Farrell","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.mayocp.2019.03.029_bib91","series-title":"The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome","author":"Ball","year":"2012"},{"key":"10.1016\/j.mayocp.2019.03.029_bib92","first-page":"Cd002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.029_bib93","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.029_bib94","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11481-018-9801-x","article-title":"Correlates of long-term opioid abstinence after randomization to methadone versus buprenorphine\/naloxone in a multi-site trial","volume":"13","author":"Zhu","year":"2018","journal-title":"J\u00a0Neuroimmune Pharmacol"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.029_bib95","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/08039480701415251","article-title":"Efficacy of maintenance treatment with methadone for opioid dependence: a meta-analytical study","volume":"61","author":"Johansson","year":"2007","journal-title":"Nord J Psychiatry"},{"issue":"5-6","key":"10.1016\/j.mayocp.2019.03.029_bib96","first-page":"347","article-title":"Methadone maintenance treatment (MMT): a review of historical and clinical issues","volume":"67","author":"Joseph","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.mayocp.2019.03.029_bib97","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.forsciint.2015.09.021","article-title":"Methadone related deaths compared to all prescription related deaths","volume":"257","author":"Lev","year":"2015","journal-title":"Forensic Sci Int"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib98","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1360-0443.1970.tb01141.x","article-title":"Methadone misuse and death by overdosage","volume":"65","author":"Gardner","year":"1970","journal-title":"Br\u00a0J\u00a0Addict Alcohol Other Drugs"},{"issue":"8","key":"10.1016\/j.mayocp.2019.03.029_bib99","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.2196\/jmir.2810","article-title":"Crowdsourcing black market prices for prescription opioids","volume":"15","author":"Dasgupta","year":"2013","journal-title":"J\u00a0Med Internet Res"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/PAF.0b013e3181e8af3d","article-title":"The methadone epidemic: methadone-related deaths on the rise in Vermont","volume":"32","author":"Madden","year":"2011","journal-title":"Am J Forensic Med Pathol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib101","doi-asserted-by":"crossref","first-page":"PL45","DOI":"10.1016\/0024-3205(94)00937-6","article-title":"The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine","volume":"56","author":"Kristensen","year":"1995","journal-title":"Life Sci"},{"issue":"14","key":"10.1016\/j.mayocp.2019.03.029_bib102","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.mayocp.2019.03.029_bib103","first-page":"Cd008025","article-title":"Methadone for chronic non-cancer pain in adults","volume":"11","author":"Haroutiunian","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mayocp.2019.03.029_bib104","first-page":"Cd002210","article-title":"LAAM maintenance vs methadone maintenance for heroin dependence","author":"Clark","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.mayocp.2019.03.029_bib105","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1360-0443.2007.01935.x","article-title":"Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status","volume":"102","author":"Anglin","year":"2007","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.029_bib106","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2047-783X-14-1-7","article-title":"Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation: results from a controlled clinical trial","volume":"14","author":"Wieneke","year":"2009","journal-title":"Eur J Med Res"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib107","first-page":"188","article-title":"The source of methadone in overdose deaths in Western Virginia in 2004","volume":"5","author":"Weimer","year":"2011","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.mayocp.2019.03.029_bib108","series-title":"Medications for Opioid Use Disorder: Treatment Improvement Protocol (TIP) Series 63","year":"2018"},{"issue":"8","key":"10.1016\/j.mayocp.2019.03.029_bib109","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/add.14199","article-title":"Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry","volume":"113","author":"Saxon","year":"2018","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.mayocp.2019.03.029_bib110","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.mayocp.2019.03.029_bib111","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/ajad.12786","article-title":"Adherence to extended release naltrexone: patient and treatment characteristics","volume":"27","author":"Chang","year":"2018","journal-title":"Am J Addict"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib112","first-page":"224","article-title":"Open-label study of injectable extended-release naltrexone (XR-NTX) in healthcare professionals with opioid dependence","volume":"11","author":"Earley","year":"2017","journal-title":"J\u00a0Addict Med"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib113","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsat.2008.01.004","article-title":"Setting the standard for recovery: Physicians' Health Programs","volume":"36","author":"DuPont","year":"2009","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.mayocp.2019.03.029_bib114","first-page":"Cd002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mayocp.2019.03.029_bib115","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"3","author":"Mattick","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mayocp.2019.03.029_bib116","first-page":"Cd002025","article-title":"Buprenorphine for managing opioid withdrawal","volume":"2","author":"Gowing","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mayocp.2019.03.029_bib117","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.drugalcdep.2015.12.035","article-title":"Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration","volume":"160","author":"Manhapra","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mayocp.2019.03.029_bib118","first-page":"Cd011983","article-title":"Supervised dosing with a long-acting opioid medication in the management of opioid dependence","volume":"4","author":"Saulle","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mayocp.2019.03.029_bib119","series-title":"Buprenorphine\/Naloxone Versus Methadone for the Treatment of Opioid Dependence: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines","year":"2016"},{"issue":"5","key":"10.1016\/j.mayocp.2019.03.029_bib120","first-page":"854","article-title":"Opioid detoxification in pregnancy","volume":"92","author":"Dashe","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib121","doi-asserted-by":"crossref","first-page":"267.e1","DOI":"10.1016\/j.ajog.2013.05.026","article-title":"The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy","volume":"209","author":"Stewart","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.03.029_bib122","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2019.03.029_bib123","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1360-0443.2012.04035.x","article-title":"Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review","volume":"107","author":"Jones","year":"2012","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.mayocp.2019.03.029_bib124","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/phar.1958","article-title":"Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women","volume":"37","author":"Tran","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib125","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.1542\/peds.2013-1985","article-title":"The transfer of drugs and therapeutics into human breast milk: an update on selected topics","volume":"132","author":"Sachs","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.mayocp.2019.03.029_bib126","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1542\/peds.2013-3524","article-title":"Neonatal abstinence syndrome","volume":"134","author":"Kocherlakota","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.mayocp.2019.03.029_bib127","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drugalcdep.2017.11.030","article-title":"Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes","volume":"185","author":"Kaltenbach","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mayocp.2019.03.029_bib128","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.brainresbull.2017.06.008","article-title":"The opioid epidemic is an historic opportunity to improve both prevention and treatment","volume":"138","author":"DuPont","year":"2018","journal-title":"Brain Res Bull"},{"issue":"4","key":"10.1016\/j.mayocp.2019.03.029_bib129","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/CHI.0b013e3181985068","article-title":"Strengths and difficulties questionnaire as a dimensional measure of child mental health","volume":"48","author":"Goodman","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.mayocp.2019.03.029_bib130","first-page":"Cd007210","article-title":"Maintenance treatments for opiate-dependent adolescents","author":"Minozzi","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.mayocp.2019.03.029_bib131","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/j.1360-0443.2010.03015.x","article-title":"Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility","volume":"105","author":"Fishman","year":"2010","journal-title":"Addiction"},{"issue":"10","key":"10.1016\/j.mayocp.2019.03.029_bib132","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archpsyc.62.10.1157","article-title":"Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial","volume":"62","author":"Marsch","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"17","key":"10.1016\/j.mayocp.2019.03.029_bib133","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.2008.574","article-title":"Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial","volume":"300","author":"Woody","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib134","first-page":"176","article-title":"A\u00a0retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine\/naloxone clinic","volume":"8","author":"Matson","year":"2014","journal-title":"J\u00a0Addict Med"},{"issue":"3","key":"10.1016\/j.mayocp.2019.03.029_bib135","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.anclin.2018.04.002","article-title":"Perioperative considerations for the patient with opioid use disorder on buprenorphine, methadone, or naltrexone maintenance therapy","volume":"36","author":"Harrison","year":"2018","journal-title":"Anesthesiol Clin"},{"issue":"1","key":"10.1016\/j.mayocp.2019.03.029_bib136","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10550887.2012.759872","article-title":"A\u00a0preliminary study comparing methadone and buprenorphine in patients with chronic pain and co-existent opioid addiction","volume":"32","author":"Neumann","year":"2013","journal-title":"J\u00a0Addict Dis"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619303933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619303933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:32:16Z","timestamp":1758418336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619619303933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":136,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0025619619303933"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.03.029","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-Assisted Treatment for Opioid-Use Disorder","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}